Determining Activity of ADC & IO Combinations Through Preclinical Tumor Models
Time: 11:30 am
day: Day 2 Track A AM
Details:
- Considerations when developing immunocompetent models to study ADC activity
- Syngeneic vs. humanized models – rationale and challenges
- Optimizing clinical relevance – dose and schedule selection
